Sponsored by:

Nuclear Medicine

AdvanCell raises $315M for targeted alpha therapy
By AuntMinnie.com staff writers
The company is developing ADVC001, a lead-212 (Pb-212)-based targeted alpha therapy for metastatic prostate cancer.
July 15, 2026
Cash Bills
Nucs AI, Segmed to build AI validation platform for theranostics
By AuntMinnie.com staff writers
The companies will develop disease-specific registries, curated research cohorts, and validation frameworks.
July 14, 2026
Artificial Intelligence Ai 400
Actineer completes Ra-226 recycling process to support Ac-225 supply
By AuntMinnie.com staff writers
This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.
July 14, 2026
Nuclear Medicine Worker Sm
Molecular Partners, Orano Med dose first patients in MP0712 trial
By AuntMinnie.com staff writers
MP0712 is a designed ankyrin repeat protein (DARPin) that targets delta-like ligand 3 (DLL3).
July 2, 2026
Nuclear Medicine
RefleXion Medical submits FDA 510(k) for Anchor Point tumor tracking
By AuntMinnie.com staff writers
RefleXion Medical is seeking FDA clearance for the company's Anchor Point Tracking tech for radiotherapy use.
June 30, 2026
Anchor Point Tracking, designed for use with the new RefleXion X2 platform, underpins SCINTIX therapy with higher fidelity biologic data.
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
By AuntMinnie.com staff writers
Deal will support Ratio's alpha therapy programs.
June 30, 2026
Business Deal Corporate 400
SNMMI mourns passing of Twyla Bartel
By AuntMinnie.com staff writers
The SNMMI is mourning the passing of one of its leading members.
June 23, 2026
Twyla Bartel, DO
AdvanCell establishes U.S. headquarters, manufacturing facility
By AuntMinnie.com staff writers
The Andover site will support development and future commercialization of ADVC001.
June 22, 2026
Nuclearmedicine
New immuno-PET tracer shows promise in prostate cancer
By Will Morton
Compared to conventional imaging, Zr-89 DFO-YS5 PET identified additional lesions.
June 15, 2026
A 74-year-old patient with metastatic prostate cancer with a positive left iliac wing lesion (SUVmax of 35.02) seen on (A) Zr-89 DFO-YS5 PET maximum projection image (MIP) and (B) PET/CT (red arrows). The lesion was graded 5 on PET but was not visible on CT (D) or (D) technitium-99 MDP bone scan.
What side effects do patients report after Pluvicto therapy?
By Will Morton
Fatigue, pain flare, nausea, and urinary symptoms are among the most commonly reported immediate side effects of Pluvicto therapy.
June 5, 2026
Post-Pluvicto SPECT/CT with axial fused images of sacrum and sagittal maximum intensity projection of one of the patients who complained of increasing pain in the sacral region (arrows) post therapy.
SNMMI ShowCast Roundup
By Will Morton
Science was the star in Los Angeles at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
June 5, 2026
Radiopharmaceutical manufacturers report uneven FDA inspections
By Liz Carey
RMTA lays out radiopharmaceutical regulatory and payment policy issues.
June 4, 2026
Lab Equipment Drug Manufacturing
Page 1 of 444
Next Page